EGFR and head and neck squamous cell carcinoma: Together, these results demonstrate that NSAIDs enhance the response to EGFR TKI and abrogate PIK3CA mutation-mediated resistance to EGFR inhibition in HNSCC cells, by the downregulation of EGFR/PI3K signaling.